Related Experiment Videos
Hydrallazine-induced Sjögren's syndrome
A Darwaza1, P J Lamey, J M Connell
1Department of Oral Medicine and Pathology, Glasgow Dental Hospital and School, Scotland.
International Journal of Oral and Maxillofacial Surgery
|April 1, 1988
Summary
Hydralazine hydrochloride, used for hypertension, can induce Sjögren
Area of Science:
- Rheumatology
- Clinical Pharmacology
Background:
- Hypertension management often involves medications with potential side effects.
- Drug-induced autoimmune syndromes are a recognized clinical concern.
Observation:
- A 60-year-old male developed Sjögren's syndrome-like symptoms after 4 years of hydralazine hydrochloride therapy.
- The patient presented with immunological features of drug-induced systemic lupus erythematosus and rheumatoid arthritis-like symptoms.
- Reduced salivary and lacrimal flow was noted, but labial gland biopsy was atypical for Sjögren's syndrome.
Findings:
- Hydralazine hydrochloride therapy was associated with the development of drug-induced systemic lupus erythematosus and Sjögren's syndrome-like features.
- Discontinuation of hydralazine hydrochloride led to the normalization of clinical parameters within one year.
Implications:
- This case highlights the potential for hydralazine hydrochloride to induce complex autoimmune presentations.
- Early recognition and withdrawal of the offending agent are crucial for managing drug-induced autoimmune syndromes.
- Further investigation into the mechanisms of hydralazine-induced autoimmunity may inform safer therapeutic strategies.